查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1467797

2024-2032 年代謝組學市場報告（按產品、適應症、應用和地區）

Metabolomics Market Report by Product, Indication, Application, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 138 Pages | 商品交期: 2-3個工作天內

價格

2023年全球IMARC Group組學市場規模達27億美元。對個人化醫療不斷成長的需求、慢性病盛行率的上升、製藥和生物技術研究的擴大以及對先進生物標記和藥物發現解決方案的需求是推動市場的一些主要因素。

代謝組學是生命科學領域的一個前沿領域，專注於生物系統內稱為代謝物的小分子的綜合研究。這些代謝物包括糖、胺基酸、脂質和其他細胞化合物等物質，它們在各種生物過程中發揮著至關重要的作用。代謝組學採用先進的分析技術（例如質譜法和核磁共振波譜法）來識別和量化這些代謝物。透過這樣做，它可以深入了解有機體的代謝狀態，提供有關健康、疾病、藥物反應和環境影響的有價值的資訊。

全球代謝組學市場正在經歷強勁成長，這主要是由於人們越來越認知到這種化合物在個人化醫療和醫療保健中發揮的關鍵作用。與此一致的是，代謝組學提供了一個強大的工具來了解個人獨特的代謝特徵，從而實現更精確的診斷、治療選擇和量身定做的醫療保健計劃，從而加強市場成長。此外，慢性病盛行率的增加以及早期疾病檢測和預防的需求正在推動對代謝組學技術的需求，為市場擴張創造了積極的前景。除此之外，廣泛採用這些技術來識別與疾病相關的代謝生物標記物，促進早期介入和監測，正在促進市場的成長。此外，製藥和生物技術研究的擴展，加上藥物發現和開發的推動，正在推動對代謝組學的需求，以闡明藥物機制、預測藥物療效和評估安全性。

代謝組學市場趨勢/促進因素：

個人化醫療的進步

代謝組學市場最重要的驅動力之一是個人化醫療的重要性日益增加。醫療保健正在擺脫一刀切的方法，代謝組學在為個別患者量身定做治療方法方面發揮關鍵作用。這種轉變很大程度上是由於人們認知到僅靠遺傳變異並不能完全了解個人的健康狀況。代謝組學透過捕捉個體代謝特徵的動態變化來補充基因組學，反映他們對疾病、藥物和環境因素的獨特反應。因此，代謝組學使醫療保健提供者能夠做出更精確的診斷、選擇個人化的治療方案並監測治療反應。例如，在癌症治療中，代謝組學可以識別患者腫瘤中失調的特定代謝途徑，幫助腫瘤學家選擇最有效的療法。

慢性病盛行率上升

糖尿病、心血管疾病和肥胖等慢性疾病的全球負擔不斷升級，是代謝組學市場的另一個重要驅動力。代謝組學為早期疾病檢測、風險評估和監測提供了強大的工具。透過分析代謝生物標記物，研究人員和臨床醫生可以識別個體代謝特徵的細微變化，這些變化可能先於疾病的臨床表現。這種早期預警系統對於實施預防措施、在疾病發展的最早階段開始治療以及追蹤疾病進展至關重要。此外，由於與生活方式相關的因素導致慢性疾病的增加，代謝組學可以揭示飲食選擇、身體活動和環境暴露如何影響個人的代謝健康。

製藥和生物技術研究

製藥和生物技術領域越來越依賴代謝組學來增強藥物發現和開發過程。代謝組學提供了對藥物機制、功效和安全性的見解，從而加速了藥物開發流程。研究人員利用代謝組學來識別和驗證藥物標靶，評估潛在候選藥物的代謝效應，並預測其藥物動力學和毒性。這些資訊有助於簡化藥物開發流程，減少代價高昂的後期失敗，並提高將創新療法推向市場的機會。此外，代謝組學對於了解藥物交互作用、最佳化給藥方案以及在臨床試驗期間監測患者反應至關重要，有助於藥物開發工作的整體效率和成功。

目錄

第1章：前言

第 2 章：範圍與方法

  • 研究目的
  • 利害關係人
  • 資料來源
    • 主要資源
    • 二手資料
  • 市場預測
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第 3 章：執行摘要

第 4 章：簡介

  • 概述
  • 主要行業趨勢

第 5 章：全球代謝組學市場

  • 市場概況
  • 市場業績
  • COVID-19 的影響
  • 市場預測

第 6 章：市場區隔：依產品

  • 代謝組學儀器
    • 市場走向
    • 市場預測
  • 代謝組學生物資訊學工具與服務
    • 市場走向
    • 市場預測

第 7 章：市場區隔：依跡象

  • 癌症
    • 市場走向
    • 市場預測
  • 心血管疾病
    • 市場走向
    • 市場預測
  • 神經系統疾病
    • 市場走向
    • 市場預測
  • 先天性代謝缺陷
    • 市場走向
    • 市場預測
  • 其他
    • 市場走向
    • 市場預測

第 8 章：市場區隔：按應用

  • 生物標記和藥物發現
    • 市場走向
    • 市場預測
  • 毒理學
    • 市場走向
    • 市場預測
  • 營養基因體學
    • 市場走向
    • 市場預測
  • 個人化醫療
    • 市場走向
    • 市場預測
  • 其他
    • 市場走向
    • 市場預測

第 9 章：市場區隔：按地區

  • 北美洲
    • 美國
      • 市場走向
      • 市場預測
    • 加拿大
      • 市場走向
      • 市場預測
  • 亞太地區
    • 中國
      • 市場走向
      • 市場預測
    • 日本
      • 市場走向
      • 市場預測
    • 印度
      • 市場走向
      • 市場預測
    • 韓國
      • 市場走向
      • 市場預測
    • 澳洲
      • 市場走向
      • 市場預測
    • 印尼
      • 市場走向
      • 市場預測
    • 其他
      • 市場走向
      • 市場預測
  • 歐洲
    • 德國
      • 市場走向
      • 市場預測
    • 法國
      • 市場走向
      • 市場預測
    • 英國
      • 市場走向
      • 市場預測
    • 義大利
      • 市場走向
      • 市場預測
    • 西班牙
      • 市場走向
      • 市場預測
    • 俄羅斯
      • 市場走向
      • 市場預測
    • 其他
      • 市場走向
      • 市場預測
  • 拉丁美洲
    • 巴西
      • 市場走向
      • 市場預測
    • 墨西哥
      • 市場走向
      • 市場預測
    • 其他
      • 市場走向
      • 市場預測
  • 中東和非洲
    • 市場走向
    • 市場細分：按國家/地區
    • 市場預測

第 10 章：SWOT 分析

  • 概述
  • 優勢
  • 弱點
  • 機會
  • 威脅

第 11 章：價值鏈分析

第 12 章：波特五力分析

  • 概述
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第13章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • Agilent Technologies Inc.
    • Biocrates Life Sciences AG
    • Bio-Rad Laboratories Inc.
    • Bruker Corporation
    • Danaher Corporation
    • Human Metabolome Technologies Inc.
    • Metabolon Inc.
    • Shimadzu Corporation
    • Thermo Fisher Scientific Inc.
    • Waters Corporation
Product Code: SR112024A2024

The global metabolomics market size reached US$ 2.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 6.5 Billion by 2032, exhibiting a growth rate (CAGR) of 10.1% during 2024-2032. The growing demand for personalized medicine, rising prevalence of chronic diseases, expanding pharmaceutical and biotechnology research, and the need for advanced biomarker and drug discovery solutions are some of the major factors propelling the market.

Metabolomics is a cutting-edge field in the realm of life sciences that focuses on the comprehensive study of small molecules called metabolites within biological systems. These metabolites include substances such as sugars, amino acids, lipids, and other cellular compounds, and they play crucial roles in various biological processes. Metabolomics employ advanced analytical techniques, such as mass spectrometry and nuclear magnetic resonance spectroscopy, to identify and quantify these metabolites. By doing so, it offers insights into an organism's metabolic state, providing valuable information about health, disease, drug responses, and environmental influences.

The global metabolomics market is experiencing robust growth, primarily driven by the growing recognition of the pivotal role that this compound plays in personalized medicine and healthcare. In line with this, metabolomics provides a powerful tool for understanding an individual's unique metabolic profile, enabling more precise diagnosis, treatment selection, and tailored healthcare plans, thereby strengthening the market growth. Moreover, the increasing prevalence of chronic diseases and the need for early disease detection and prevention are boosting demand for metabolomics technologies, creating a positive outlook for market expansion. In addition to this, the widespread adoption of these technologies to identify metabolic biomarkers associated with diseases, facilitating early intervention and monitoring, is contributing to the market's growth. Furthermore, the expansion of pharmaceutical and biotechnology research, coupled with the drive for drug discovery and development, is fueling demand for metabolomics to elucidate drug mechanisms, predict drug efficacy, and assess safety.

Metabolomics Market Trends/Drivers:

Advancements in personalized medicine

One of the foremost drivers of the metabolomics market is the increasing importance of personalized medicine. Healthcare is moving away from a one-size-fits-all approach, and metabolomics plays a pivotal role in tailoring treatments to individual patients. This shift is largely due to the recognition that genetic variations alone do not provide a complete understanding of an individual's health. Metabolomics complements genomics by capturing dynamic changes in an individual's metabolic profile, reflecting their unique response to diseases, drugs, and environmental factors. As a result, metabolomics enables healthcare providers to make more precise diagnoses, select personalized treatment options, and monitor therapeutic responses. For example, in cancer treatment, metabolomics can identify specific metabolic pathways that are dysregulated in a patient's tumor, helping oncologists choose the most effective therapies.

Rising prevalence of chronic diseases

The escalating global burden of chronic diseases including diabetes, cardiovascular disorders, and obesity is another significant driver of the metabolomics market. Metabolomics provides a powerful tool for early disease detection, risk assessment, and monitoring. By analyzing metabolic biomarkers, researchers and clinicians can identify subtle changes in an individual's metabolic profile that may precede the clinical manifestation of a disease. This early warning system is crucial for implementing preventive measures, initiating treatments at the earliest stages of disease development, and tracking disease progression. Additionally, as lifestyle-related factors contribute to the rise in chronic diseases, metabolomics can shed light on how dietary choices, physical activity, and environmental exposures impact an individual's metabolic health.

Pharmaceutical and biotechnology research

The pharmaceutical and biotechnology sectors are increasingly relying on metabolomics to enhance drug discovery and development processes. Metabolomics offers insights into drug mechanisms, efficacy, and safety, thereby accelerating the drug development pipeline. Researchers use metabolomics to identify and validate drug targets, assess the metabolic effects of potential drug candidates, and predict their pharmacokinetics and toxicity. This information helps streamline the drug development process, reduce costly late-stage failures, and improve the chances of bringing innovative therapies to market. Moreover, metabolomics is crucial for understanding drug interactions, optimizing dosing regimens, and monitoring patient responses during clinical trials, contributing to the overall efficiency and success of drug development efforts.

Metabolomics Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global metabolomics market report, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on product, indication, and application.

Breakup by Product:

Metabolomics Instruments

Metabolomics Bioinformatics Tools and Services

Metabolomics bioinformatics tools and services dominate the market

The report has provided a detailed breakup and analysis of the market based on the product. This includes metabolomics instruments and metabolomics bioinformatics tools and services. According to the report, metabolomics bioinformatics tools and services represented the largest segment.

The demand for metabolomics bioinformatic tools and services is mainly propelled by the complexity and volume of data generated in metabolomics research. Metabolomics experiments produce vast datasets with intricate molecular information, making data analysis and interpretation a significant challenge. Besides this, metabolomics bioinformatic tools and services are essential for processing, managing, and extracting meaningful insights from this wealth of data. Furthermore, the integration of multi-omics data, including genomics, proteomics, and metabolomics, is becoming increasingly crucial to gain a holistic understanding of biological systems. To harness the full potential of metabolomics data, researchers require sophisticated software solutions and expert services that can handle data preprocessing, statistical analysis, pathway mapping, and biomarker identification. As metabolomics continues to expand its applications in diverse fields, the demand for bioinformatic tools and services is set to rise, enabling researchers to unlock the valuable information hidden within their datasets.

Breakup by Indication:

Cancer

Cardiovascular Disorders

Neurological Disorders

Inborn Errors of Metabolism

Others

Cancer holds the largest share in the market

A detailed breakup and analysis of the market based on the indication has also been provided in the report. This includes cancer, cardiovascular disorders, neurological disorders, inborn errors of metabolism, and others. According to the report, cancer accounted for the largest market share.

The urgent need for more precise and early detection methods, as well as personalized treatment strategies in cancer research and diagnostics is strengthening the demand for metabolomics. They offer a unique advantage in cancer studies by providing a real-time snapshot of an individual's metabolic profile, allowing for the identification of specific metabolic alterations associated with different types and stages of cancer. These metabolic signatures can serve as potential biomarkers for early cancer detection, enabling clinicians to detect malignancies at a more treatable stage. Furthermore, as cancer treatment often leads to metabolic changes and varying responses in patients, metabolomics can assist in tailoring therapeutic approaches by monitoring how a patient's metabolism reacts to specific cancer treatments. This personalized approach has the potential to enhance treatment outcomes and minimize adverse effects, driving the demand for metabolomics applications in the field of oncology.

Breakup by Application:

Biomarker and Drug Discovery

Toxicology

Nutrigenomics

Personalized Medicine

Others

Biomarker and drug discovery dominates the market

The report has provided a detailed breakup and analysis of the market based on the application. This includes biomarker and drug discovery, toxicology, nutrigenomics, personalized medicine, and others. According to the report, biomarker and drug discovery represented the largest segment.

The burgeoning demand for metabolomics in biomarker and drug discovery applications is driven by its unparalleled ability to unveil novel biomarkers and therapeutic targets. Metabolomics allows researchers to delve deep into an organism's biochemical landscape, identifying subtle metabolic changes associated with diseases and drug responses that may go unnoticed by other omics techniques. This capability is invaluable in biomarker discovery, where metabolomics can pinpoint specific metabolites indicative of disease presence, progression, or treatment efficacy. Additionally, in drug discovery, metabolomics plays a pivotal role in elucidating drug mechanisms and assessing potential drug candidates' safety profiles by uncovering their metabolic impact. By providing a comprehensive view of the intricate interactions within biological systems, metabolomics accelerates the identification of promising drug targets, expedites the development of new therapies, and minimizes the risk of late-stage drug failures, thereby fueling the demand for metabolomics in these critical areas of research.

Breakup by Region:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America exhibits a clear dominance, accounting for the largest metabolomics market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

North America boasts a thriving biopharmaceutical and healthcare industry, characterized by substantial investments in research and development (R&D). This robust ecosystem fuels the demand for metabolomics technologies in drug discovery and personalized medicine applications, as pharmaceutical companies seek innovative solutions to expedite drug development and enhance patient care. Concurrent with this, the region's healthcare infrastructure places a strong emphasis on precision medicine, with government initiatives and healthcare institutions increasingly recognizing the potential of metabolomics for tailoring treatments and improving patient outcomes. Furthermore, collaborations between academic research institutions and industry players in North America have paved the way for cutting-edge metabolomics research, further propelling the market's growth. These factors, combined with a favorable regulatory environment, position North America as a key hub for metabolomics innovation and adoption, driving the market forward.

Competitive Landscape:

The competitive landscape of the global metabolomics market is dynamic and characterized by intense competition among both established players and emerging companies. Leading companies dominate the market with their comprehensive portfolios of metabolomics instruments, software, and services. These industry giants focus on continuous innovation, strategic partnerships, and acquisitions to expand their market presence and offer integrated solutions to customers. Additionally, academic institutions and research organizations contribute significantly to the market by developing cutting-edge metabolomics technologies and methodologies and fostering collaborations with industry stakeholders. Emerging startups, specializing in niche metabolomics applications, are also gaining traction by introducing innovative tools and services, enhancing competition and driving market growth. Furthermore, the market's global nature makes it highly competitive on a regional basis, with regional players catering to specific geographical preferences and regulations.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

Agilent Technologies Inc.

Biocrates Life Sciences AG

Bio-Rad Laboratories Inc.

Bruker Corporation

Danaher Corporation

Human Metabolome Technologies Inc.

Metabolon Inc.

Shimadzu Corporation

Thermo Fisher Scientific Inc.

Waters Corporation

Recent Developments:

In June 2021, Bruker Corporation unveiled the FluoroTypeSARS-CoV-2 Varied Q assay, a quantitative Liquid Array mid-plexPCR panel that identifies the presence of the virus and detects key mutations, allowing laboratories and hospitals to routinely distinguish between major viral variants in positive samples.

In June 2021, Thermo Fischer Scientific launched the Orbitrap IQ-X Tribrid mass spectrometer, the latest in their Next-Generation MS-Based Solutions lineup, designed specifically to elucidate intricate chemical structures for precise compound identification.

Key Questions Answered in This Report:

  • How has the global metabolomics market performed so far, and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global metabolomics market?
  • What is the impact of each driver, restraint, and opportunity on the global metabolomics market?
  • What are the key regional markets?
  • Which countries represent the most attractive metabolomics market?
  • What is the breakup of the market based on the product?
  • Which is the most attractive product in the metabolomics market?
  • What is the breakup of the market based on the indication?
  • Which is the most attractive indication in the metabolomics market?
  • What is the breakup of the market based on the application?
  • Which is the most attractive application in the metabolomics market?
  • What is the competitive structure of the global metabolomics market?
  • Who are the key players/companies in the global metabolomics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Metabolomics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product

  • 6.1 Metabolomics Instruments
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Metabolomics Bioinformatics Tools and Services
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Indication

  • 7.1 Cancer
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Cardiovascular Disorders
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Neurological Disorders
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Inborn Errors of Metabolism
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Others
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by Application

  • 8.1 Biomarker and Drug Discovery
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Toxicology
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Nutrigenomics
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Personalized Medicine
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Others
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Competitive Landscape

  • 13.1 Market Structure
  • 13.2 Key Players
  • 13.3 Profiles of Key Players
    • 13.3.1 Agilent Technologies Inc.
      • 13.3.1.1 Company Overview
      • 13.3.1.2 Product Portfolio
      • 13.3.1.3 Financials
      • 13.3.1.4 SWOT Analysis
    • 13.3.2 Biocrates Life Sciences AG
      • 13.3.2.1 Company Overview
      • 13.3.2.2 Product Portfolio
    • 13.3.3 Bio-Rad Laboratories Inc.
      • 13.3.3.1 Company Overview
      • 13.3.3.2 Product Portfolio
      • 13.3.3.3 Financials
      • 13.3.3.4 SWOT Analysis
    • 13.3.4 Bruker Corporation
      • 13.3.4.1 Company Overview
      • 13.3.4.2 Product Portfolio
      • 13.3.4.3 Financials
    • 13.3.5 Danaher Corporation
      • 13.3.5.1 Company Overview
      • 13.3.5.2 Product Portfolio
      • 13.3.5.3 Financials
      • 13.3.5.4 SWOT Analysis
    • 13.3.6 Human Metabolome Technologies Inc.
      • 13.3.6.1 Company Overview
      • 13.3.6.2 Product Portfolio
      • 13.3.6.3 Financials
    • 13.3.7 Metabolon Inc.
      • 13.3.7.1 Company Overview
      • 13.3.7.2 Product Portfolio
    • 13.3.8 Shimadzu Corporation
      • 13.3.8.1 Company Overview
      • 13.3.8.2 Product Portfolio
      • 13.3.8.3 Financials
      • 13.3.8.4 SWOT Analysis
    • 13.3.9 Thermo Fisher Scientific Inc.
      • 13.3.9.1 Company Overview
      • 13.3.9.2 Product Portfolio
      • 13.3.9.3 Financials
      • 13.3.9.4 SWOT Analysis
    • 13.3.10 Waters Corporation
      • 13.3.10.1 Company Overview
      • 13.3.10.2 Product Portfolio
      • 13.3.10.3 Financials
      • 13.3.10.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Metabolomics Market: Major Drivers and Challenges
  • Figure 2: Global: Metabolomics Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Metabolomics Market: Breakup by Product (in %), 2023
  • Figure 4: Global: Metabolomics Market: Breakup by Indication (in %), 2023
  • Figure 5: Global: Metabolomics Market: Breakup by Application (in %), 2023
  • Figure 6: Global: Metabolomics Market: Breakup by Region (in %), 2023
  • Figure 7: Global: Metabolomics Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 8: Global: Metabolomics (Metabolomics Instruments) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Metabolomics (Metabolomics Instruments) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Metabolomics (Metabolomics Bioinformatics Tools and Services) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Metabolomics (Metabolomics Bioinformatics Tools and Services) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Metabolomics (Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Metabolomics (Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Metabolomics (Cardiovascular Disorders) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Metabolomics (Cardiovascular Disorders) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Metabolomics (Neurological Disorders) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Metabolomics (Neurological Disorders) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Metabolomics (Inborn Errors of Metabolism) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Metabolomics (Inborn Errors of Metabolism) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Metabolomics (Other Indications) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Metabolomics (Other Indications) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Metabolomics (Biomarker and Drug Discovery) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Metabolomics (Biomarker and Drug Discovery) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Metabolomics (Toxicology) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Metabolomics (Toxicology) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: Metabolomics (Nutrigenomics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: Metabolomics (Nutrigenomics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: Global: Metabolomics (Personalized Medicine) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: Global: Metabolomics (Personalized Medicine) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: Global: Metabolomics (Other Applications) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: Global: Metabolomics (Other Applications) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: North America: Metabolomics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: North America: Metabolomics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: United States: Metabolomics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: United States: Metabolomics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: Canada: Metabolomics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: Canada: Metabolomics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: Asia Pacific: Metabolomics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: Asia Pacific: Metabolomics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: China: Metabolomics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: China: Metabolomics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: Japan: Metabolomics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: Japan: Metabolomics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: India: Metabolomics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: India: Metabolomics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: South Korea: Metabolomics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: South Korea: Metabolomics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Australia: Metabolomics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Australia: Metabolomics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Indonesia: Metabolomics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Indonesia: Metabolomics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: Others: Metabolomics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: Others: Metabolomics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: Europe: Metabolomics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: Europe: Metabolomics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: Germany: Metabolomics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: Germany: Metabolomics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: France: Metabolomics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: France: Metabolomics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: United Kingdom: Metabolomics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: United Kingdom: Metabolomics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Italy: Metabolomics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Italy: Metabolomics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Spain: Metabolomics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Spain: Metabolomics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Russia: Metabolomics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Russia: Metabolomics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Others: Metabolomics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Others: Metabolomics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Latin America: Metabolomics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Latin America: Metabolomics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Brazil: Metabolomics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Brazil: Metabolomics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Mexico: Metabolomics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 75: Mexico: Metabolomics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 76: Others: Metabolomics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 77: Others: Metabolomics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 78: Middle East and Africa: Metabolomics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 79: Middle East and Africa: Metabolomics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 80: Global: Metabolomics Industry: SWOT Analysis
  • Figure 81: Global: Metabolomics Industry: Value Chain Analysis
  • Figure 82: Global: Metabolomics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Metabolomics Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Metabolomics Market Forecast: Breakup by Product (in Million US$), 2024-2032
  • Table 3: Global: Metabolomics Market Forecast: Breakup by Indication (in Million US$), 2024-2032
  • Table 4: Global: Metabolomics Market Forecast: Breakup by Application (in Million US$), 2024-2032
  • Table 5: Global: Metabolomics Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Metabolomics Market: Competitive Structure
  • Table 7: Global: Metabolomics Market: Key Players